KalVista misses earnings but EKTERLY launch gains momentum
Oral HAE treatment captures 20% of US market as company eyes profitability
KalVista Pharmaceuticals reported a wider-than-expected loss of $2.03 per share for the eight months ended December 31, missing analyst estimates of -$0.92, as the biotechnology company invested heavily in commercializing its flagship HAE treatment EKTERLY. The shares edged down 0.8% to $16.46 in morning trading, giving the company a market capitalization of $839 million.
The red ink reflects $124.7 million in selling, general and administrative expenses during the transition period, driven by commercialization costs for EKTERLY. Despite the earnings shortfall, investors are focusing on what the numbers reveal about product adoption rather than the burn rate.
EKTERLY generated $49.1 million in global net product revenue during the eight-month period, with the US launch beginning July 7, 2025, following FDA approval as the first and only oral on-demand treatment for hereditary angioedema attacks. The company has secured 1,702 patient start forms in the US through the end of February, representing approximately 20% of the treated US HAE patient population. The drug has been prescribed by 724 unique healthcare providers, indicating broad acceptance among physicians.
"We've achieved rapid market penetration in a relatively short timeframe," analysts noted in the earnings aftermath, pointing to the oral formulation's competitive advantage against injectable alternatives. The hereditary angioedema treatment market is valued at $6.83 billion globally and projected to reach $14.69 billion by 2031, with North America representing the dominant region.
KalVista's financial position provides substantial runway. The company reported $300.2 million in cash, cash equivalents, and marketable securities as of December 31, 2025, which management stated is sufficient to fund operations through profitability. This cash buffer provides flexibility as the company scales its commercial operations and continues clinical development.
A significant milestone announced alongside earnings was completion of enrollment in the Phase 3 KONFIDENT-KID pediatric trial for children aged 2 to 11 years, achieved a year ahead of schedule. KalVista plans to submit a new drug application for this younger patient population in the third quarter of 2026, with a potential US launch in 2027. The company will present late-breaking data from the pediatric trial at the Global Angioedema Leadership Conference in Madrid from March 26-29, 2026.
The competitive landscape for HAE treatments includes both prophylactic and on-demand therapies. BioCryst Pharmaceuticals offers ORLADEYO, a once-daily oral prophylactic treatment, and is developing navenibart, a long-acting monoclonal antibody. CSL Behring markets HAEGARDA and BERINERT as injectable options, while Takeda offers TAKHZYRO prophylaxis and FIRAZYR for acute attacks.
Wall Street maintains a bullish outlook on KalVista despite the earnings miss. Analysts have a consensus "Strong Buy" rating with a median price target of $34.00, implying more than 100% upside from current levels. Of the 14 analysts covering the stock, nine rate it a "Buy" and two a "Strong Buy," with no hold or sell ratings.
The shift in fiscal year from April 30 to December 31 created the unusual eight-month reporting period, making year-over-year comparisons challenging. Looking ahead to the full year 2026, investors will be watching for continued uptake of EKTERLY, progress on the pediatric indication, and potential international expansion beyond the markets where approval has already been secured—including the UK, European Union, Switzerland, Australia, Singapore, and Japan.